The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | BOSTON: SVd shows clinical benefit in myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on the Phase III BOSTON study (NCT03110562) trialling bortezomib plus selinexor and dexamethasone (SVd) in patients with multiple myeloma. Selinexor is a selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins. Thus far, SVd has shows significant clinical benefit and reduced peripheral neuropathy compared with standard twice-weekly bortezomib plus dexamethasone in multiple myeloma patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
